WO2012120387A1 - Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof - Google Patents

Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof Download PDF

Info

Publication number
WO2012120387A1
WO2012120387A1 PCT/IB2012/050527 IB2012050527W WO2012120387A1 WO 2012120387 A1 WO2012120387 A1 WO 2012120387A1 IB 2012050527 W IB2012050527 W IB 2012050527W WO 2012120387 A1 WO2012120387 A1 WO 2012120387A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanochannel
biomolecules
biosensor
solution
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/050527
Other languages
French (fr)
Inventor
Nicolas Durand
Iwan MÄRKI
Stéphane BROILLET
Annick MAYOR
Theo Lasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionic SA
Original Assignee
Abionic SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abionic SA filed Critical Abionic SA
Priority to US14/003,277 priority Critical patent/US9547004B2/en
Priority to CN201280012408.XA priority patent/CN103502795B/en
Priority to EP12711449.4A priority patent/EP2684027B1/en
Priority to AU2012226463A priority patent/AU2012226463B2/en
Priority to JP2013557188A priority patent/JP6130306B2/en
Priority to ES12711449T priority patent/ES2767123T3/en
Priority to BR112013022952-7A priority patent/BR112013022952B1/en
Priority to HK14100834.4A priority patent/HK1187982B/en
Priority to CA2829178A priority patent/CA2829178C/en
Publication of WO2012120387A1 publication Critical patent/WO2012120387A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502746—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means for controlling flow resistance, e.g. flow controllers, baffles or throttle valves
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6452—Individual samples arranged in a regular 2D-array, e.g. multiwell plates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0877—Flow chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y35/00—Methods or apparatus for measurement or analysis of nanostructures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/01—Arrangements or apparatus for facilitating the optical investigation
    • G01N21/03—Cuvette constructions
    • G01N2021/0346—Capillary cells; Microcells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/01—Arrangements or apparatus for facilitating the optical investigation
    • G01N21/03—Cuvette constructions
    • G01N21/05—Flow-through cuvettes
    • G01N2021/058—Flat flow cell

Definitions

  • the present invention relates to methods and devices for the detection of fluorescently labeled biomolecules in selectively functionalized nanofluidic biosensors, using an optical system.
  • the present invention may advantageously be used for rapid quantification of biomedical and biological samples.
  • Nanofluidic biosensors are defined as fluidic systems with nanometer- sized confinements and/or lateral apertures, which are used to quantify the presence of biomolecules in a solution.
  • a majority of the current nanofluidic biosensor developments are intended for bioengineering and biotechnology applications.
  • biosensors are used to quantify the presence of biomolecules in solution for in vitro diagnostic applications.
  • Swiss patent application CH 01824/09 discloses biosensors with lateral apertures for the detection of biomolecular interactions
  • PCT application IB2010/050867 discloses their use with simple optical systems. The diffusion of biomolecules in these configurations are slow and require either long waiting times to attain stable measurement conditions or highly concentrated solutions for the observation of the biomolecular interactions.
  • Biomarkers also called biological markers, are substances used as specific indicators for detecting the presence of biomolecules. It is a characteristic that is objectively measured and evaluated as an indicator of biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
  • electrochemical biosensors referring to amperometric, capacitive, conductometric or impedimetric sensors, which have the advantage of being rapid and inexpensive. They measure the change in electrical properties of electrode structures as biomolecules become entrapped or immobilized onto or near the electrode, but all these concepts lack molecular specific contrast, sensitivity and reliability.
  • Enzyme linked immunosorbent assay is an important biochemical technique mainly used to detect the presence of soluble biomolecules in serum, and thus is widely used as diagnostic tool in medicine and quality control check in various industries. ELISA analysis are however expensive, require large amounts of solution and is time consuming.
  • Still another object of the invention is to geometrically confine the optical measurement volume using nanofluidics, and to selectively functionalize nanochannel surfaces in order to obtain a high sensitivity of the biosensor.
  • Still another object of the invention is to enhance the sensitivity of the detection by forcing a convective flow across a nanometer-sized confinement (nanochannel) in order to increase the probability for the biomolecules to interact with immobilized biomarkers.
  • This invention is based on the discovery that forcing biomolecules to enter into a nanometer sized confinement that has selectively functionalized surfaces strongly increase the probability for the biomolecules to interact with immobilized biomarkers. This allows quantifying the presence of fluorescently-labeled biomolecules at ultra-low concentration.
  • This invention is also based on the discovery that monitoring the photobleaching of the fluophores attached to the biomolecules can be used to differentiate between biomolecules that have interacted with biomarkers and are immobilized in the nanochannel, and those that are simply diffusing through the detection volume.
  • this invention highlights the possibility to use a driving component to force the convective flow of the solution to analyze through the nanochannel.
  • the term "driving component” has to be understood as any element, for instance an absorbing element, which can be used for facilitating the solution flow through the nanochannel.
  • nanofluidics is used because of its high surface- to-volume ratio, meaning that the surfaces included in the detection volume, maximize the probability of the interactions between biomolecules and immobilized biomarkers on surfaces. It also strongly reduces the background signal of the solution due to the small portion of substrate that is within the detection volume.
  • the invention therefore relates to a biosensor as defined in the claims. [0021] It also relates to an assembly and a method using said biosensor.
  • FIGURE la is a perspective view of a capsule system 101 containing an array of nanofluidic biosensors 200.
  • a solution 300 containing fluorescently-labeled biomolecules is deposited inside the capsule 101 by a pipet system 400.
  • An optical system 500 based on a laser beam 510 is used for the measurement.
  • FIGURE lb is a perspective view of a surface 102 containing an array of nanofluidic biosensors 200.
  • a solution 300 containing fluorescently-labeled biomolecules is deposited on the surface 102 by a pipet system 400.
  • An optical system 500 based on a laser beam 510 is used for the measurement.
  • FIGURE 2a shows a cross section of the nanofluidic biosensor defined by two substrates 201 and 202 that are locally structured by areas 211 that are functionalized by biomarkers 310 and other areas 203 that prevent that functionalization.
  • Reagent solution 300 containing biomolecules enter the nanochannel 210 and is actuated by the external driving component 241.
  • the laser beam 510 monitors the photobleaching of the immobilized biomolecules 340 in the detection volume 520.
  • FIGURE 2b shows a cross section of the nanofluidic biosensor defined by two substrates 201 and 202. Only one of the substrates is locally structured by area 211 that is functionalized by biomarkers 310 and other areas 203 that prevent that functionalization.
  • Reagent solution 300 containing biomolecules enter the nanochannel 210 and is actuated by the internal driving component 242.
  • the laser beam 510 monitors the photobleaching of the immobilized biomolecules 340 in the detection volume 520.
  • FIGURE 3 illustrates the concentration evolution with time of specific biomolecules over the nanochannel length.
  • FIGURE 4 shows the concentration profile of specific biomolecules over the nanochannel length for a given time t ⁇ .
  • the marked area represents the detected portion of specific biomolecules.
  • FIGURE 5 illustrates the concentration evolution with time of non-specific biomolecules (background) over the nanochannel length.
  • FIGURE 6 shows the concentration profile of non-specific biomolecules over the nanochannel length for a given time t ⁇ .
  • the marked area represents the detected portion of specific biomolecules, corresponding to the background noise.
  • FIGURE 7 illustrates a standard photobleaching curve of fluorophores attached to immobilized specific biomolecules.
  • FIGURE 8 illustrates the fluorescence intensity curve in function of time for non-specific biomolecules inside the nanochannel, showing that only background noise is detected.
  • FIGURE 9 shows the solution flow velocity inside the nanochannel in function of time.
  • biomolecules is intended to be a generic term, which includes for example (but not limited to) proteins such as antibodies or cytokines, peptides, nucleic acids, lipid molecules, polysaccharides and virus.
  • nanochannel is intended to be a generic term, which means well-defined microfabricated structure with at least one nanometer-sized dimension.
  • the nanometer- sized dimension of the nanochannel is defined to be higher than 2 nm because of the size of the smallest biomolecules to be detected that have to enter into the slit and that are in the same order of magnitude.
  • the present invention is limited to nanochannels with a height lower than one micron, because of the range of the detection volume of the optical system that are typically in the same order of magnitude.
  • the present invention aims to enhance the detection of biomolecules by increasing the probability of interactions with specific biomarkers due to the confinement of functionalized surfaces.
  • an array of nanofluidic biosensors 200 is immobilized in a capsule system 101 or on a surface 102.
  • a mix solution 300 containing the fluorescently-labeled biomolecules of interest is disposed inside the capsule 101 or on the surface 102 by a pipet system 400.
  • the capsule 101 may be hermetically closed in order to avoid contamination.
  • an optical unit 500 is used to measure the biomolecular interactions inside the biosensors 200 by focusing the laser beam 510 inside the biosensors nanochannel.
  • FIGURE 2a and FIGURE 2b illustrate the principle of detection and the cross-section of a biosensor according to the invention.
  • the system is composed of a nanochannel 210 linking a lateral input aperture 220 with a lateral output aperture 230.
  • a driving component that can be external (241) or internal (242) is located next to the lateral output aperture 230.
  • biomarkers 310 are immobilized on selectively functionalized nanochannel surfaces of one or both substrates 201 and 202. The other nanochannel surfaces and the lateral aperture surfaces may be protected by the deposition of a non-functionalized layer 203.
  • the detection volume 520 has to be focused inside the nanochannel 210 such as the intersection volume defined by the volume of the nanochannel 210 and the detection volume 520 is maximal, and directly next to the lateral input aperture 220.
  • the solution 300 containing the fluorescently labeled specific biomolecules 320 and non-specific biomolecules 330 is filled into the system from the lateral input aperture 220 by capillarity.
  • the driving component 241 or 242 the solution 300 fills the driving component by absorption for example, leading to a forced convective flow across the biosensor.
  • the driving component 241 or 242 achieves its maximum filling capacity, the convective flow stops and the system reaches equilibrium.
  • biomolecules 320 interact with the biomarkers 310 immobilized inside the nanochannel 210 and may create molecular complexes 340.
  • a concentration gradient is obtained across the nanochannel 210.
  • the non-specific biomolecules 330 will diffuse in the nanochannel 210 but will not form molecular complexes with the immobilized biomarkers 310.
  • Non-specific biomolecules 331 will be present in the lateral output aperture 230, and some 332 may also be present inside the driving component 241 or 242.
  • the immobilized fluorescently emitting complexes 340 and the diffusing fluorescently emitting biomolecules 330 diffusing across the optical detection volume are both detected by the optical system.
  • the present invention is distinguishable from techniques currently being used to detect molecular interactions.
  • the unique method of measuring the concentration of immobilized complexes across the selectively functionalized nanochannel being linked to lateral apertures is different from current techniques based on measuring interactions on a single surface or reservoir. These solutions do not benefit from the increased probability of interaction events that occur in the unique design presented in this patent.
  • FIGURE 3 shows the evolution of concentration with time across the biosensor when the solution contains specific biomolecules.
  • a background concentration c 0 of fluorescently labeled molecules inside the lateral input aperture.
  • Specific biomolecules that enter into the nanochannel interact quickly with the nanochannel functionalized surfaces, leading to an increase of concentration (dashed curve).
  • the maximum concentration c sat corresponds to the case where, for a given x position, all biomarkers have interacted with specific biomolecules.
  • the concentration gradient will tend to the t lnf dotted curve, corresponding to the total saturation of the nanochannel biomarkers (dotted curve).
  • FIGURE 4 illustrates the concentration gradient across the biosensor at a time t 1; corresponding to the case when the solution has already filled the biosensor as well as the absorbing component. Thanks to Brownian motion, the biomolecules continue to enter the nanochannel and continue to interact with the biomarkers, but depending on the background concentration c 0 , the transition to saturation t inf may be very long. This allows a stable measurement of the concentration profile across the nanochannel.
  • the measurement volume (hatched area) corresponds to the intersection of the laser beam with a width b and the nanochannel.
  • FIGURE 5 shows the concentration evolution with time across the biosensor when the solution contains only non-specific biomolecules.
  • a background concentration Co of fluorescently labeled molecules is present inside the lateral input aperture and the nanochannel. No further concentration increase is expected as there is no interaction with the functionalized surfaces. In this case, the concentration Co remains constant for all x positions and with time.
  • FIGURE 6 illustrates the concentration gradient across the biosensor at a time ti, corresponding to the case when the solution contains no specific biomolecules and has already filled the biosensor as well as the absorbing component.
  • the measurement volume (hatched area) corresponds to the intersection of the laser beam with a width b and the nanochannel.
  • FIGURE 7 shows the fluorescence intensity evolution with time during measurement, for a given position inside the nanochannel, when the solution contains specific biomolecules. The measurement starts when the shutter of the optical system opens. A standard photobleaching curve is obtained containing quantitative information on the number of immobilized and fluorescently-labeled molecules present within the measurement volume.
  • FIGURE 8 shows the fluorescence intensity evolution with time during a measurement, for a given position inside the nanochannel, when the solution does not contain any specific biomolecules.
  • the measurement starts when the shutter of the optical system opens. No photobleaching curve is obtained, since there are only diffusing fluorescently-labeled biomolecules inside the measurement volume leading to a constant background signal.
  • FIGURE 9 shows the evolution of the convective flow of the solution inside the nanochannel in function of time.
  • the nanochannel is filled by capillarity during a time t cap , which results in an increase of the flow velocity.
  • the solution has completely filled the nanochannel and the flow is no more driven by capillarity but rather by absorption. This results in a change of flow velocity during a time t act .
  • the solution flow inside the nanochannel tends to 0, and biomolecule movements are only due to Brownian motion. Measuring time t m should occur after the convective flow stopped.
  • the device offers great improvements for the detection, enumeration, identification and characterization of biomolecules interacting or not with other immobilized biomolecules.
  • Applications of the present invention can cover biomedical, biological or food analysis as well as fundamental studies in analytical and bioanalytical chemistry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

A method and device for the rapid quantification of biomolecules (320) present in a nanochannel (210) is claimed. In particular, the present invention relates to a novel concept of liquid actuation and selectively functionalized surfaces in a nanochannel that create a concentration gradient of transitory immobilized biomolecules (340) across the nanochannel. The present concept enables the quantification of biomolecular interactions of interest (320).

Description

RAPID QUANTIFICATION OF BIOMOLECULES IN A SELECTIVELY FUNCTIONALIZED NANOFLUIDIC BIOSENSOR AND METHOD THEREOF
Field of invention
[0001] The present invention relates to methods and devices for the detection of fluorescently labeled biomolecules in selectively functionalized nanofluidic biosensors, using an optical system. The present invention may advantageously be used for rapid quantification of biomedical and biological samples.
Background of the invention
[0002] Nanofluidic biosensors are defined as fluidic systems with nanometer- sized confinements and/or lateral apertures, which are used to quantify the presence of biomolecules in a solution. A majority of the current nanofluidic biosensor developments are intended for bioengineering and biotechnology applications. In the scope of this invention, biosensors are used to quantify the presence of biomolecules in solution for in vitro diagnostic applications.
[0003] Swiss patent application CH 01824/09 discloses biosensors with lateral apertures for the detection of biomolecular interactions and PCT application IB2010/050867 discloses their use with simple optical systems. The diffusion of biomolecules in these configurations are slow and require either long waiting times to attain stable measurement conditions or highly concentrated solutions for the observation of the biomolecular interactions.
[0004] Biomarkers, also called biological markers, are substances used as specific indicators for detecting the presence of biomolecules. It is a characteristic that is objectively measured and evaluated as an indicator of biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
[0005] Current practices for the detection of specific biomolecules can be divided in two categories: (a) the labeled techniques and (b) the label-free techniques. [0006] Among the labeled techniques, the widely used are fluorescence, colorimetry, radioactivity, phosphorescence, bioluminescence and chemiluminescence. Functionalized magnetic beads can also be considered as labeling techniques. Labeled techniques advantages are the sensitivity in comparison to label-free methods and the molecular recognition due to specific labeling.
[0007] Among the label-free techniques, the widely used are electrochemical biosensors, referring to amperometric, capacitive, conductometric or impedimetric sensors, which have the advantage of being rapid and inexpensive. They measure the change in electrical properties of electrode structures as biomolecules become entrapped or immobilized onto or near the electrode, but all these concepts lack molecular specific contrast, sensitivity and reliability.
[0008] Enzyme linked immunosorbent assay (ELISA) is an important biochemical technique mainly used to detect the presence of soluble biomolecules in serum, and thus is widely used as diagnostic tool in medicine and quality control check in various industries. ELISA analysis are however expensive, require large amounts of solution and is time consuming.
[0009] The other important technologies for biomolecular diagnostics are Western and Northern blots, protein electrophoresis and polymerase chain reaction (PCR). However, these methods require highly concentrated analytes and do not allow high throughput samples testing.
Objectives
[0010] It is an object of this invention to provide inexpensive and rapid nanofluidic biosensors, which do not require complex manipulations.
[0011] Still another object of the invention is to geometrically confine the optical measurement volume using nanofluidics, and to selectively functionalize nanochannel surfaces in order to obtain a high sensitivity of the biosensor.
[0012] Still another object of the invention is to enhance the sensitivity of the detection by forcing a convective flow across a nanometer-sized confinement (nanochannel) in order to increase the probability for the biomolecules to interact with immobilized biomarkers.
[0013] These and other objects of the present invention will become increasingly apparent with reference to the following drawings and preferred embodiments.
Summary of the invention
[0014] This invention is based on the discovery that forcing biomolecules to enter into a nanometer sized confinement that has selectively functionalized surfaces strongly increase the probability for the biomolecules to interact with immobilized biomarkers. This allows quantifying the presence of fluorescently-labeled biomolecules at ultra-low concentration.
[0015] This invention is also based on the discovery that monitoring the photobleaching of the fluophores attached to the biomolecules can be used to differentiate between biomolecules that have interacted with biomarkers and are immobilized in the nanochannel, and those that are simply diffusing through the detection volume.
[0016] Furthermore, this invention highlights the possibility to use a driving component to force the convective flow of the solution to analyze through the nanochannel.
[0017] In the present text the term "driving component" has to be understood as any element, for instance an absorbing element, which can be used for facilitating the solution flow through the nanochannel.
[0018]
[0019] In the scope of this invention, nanofluidics is used because of its high surface- to-volume ratio, meaning that the surfaces included in the detection volume, maximize the probability of the interactions between biomolecules and immobilized biomarkers on surfaces. It also strongly reduces the background signal of the solution due to the small portion of substrate that is within the detection volume.
[0020] The invention therefore relates to a biosensor as defined in the claims. [0021] It also relates to an assembly and a method using said biosensor.
Brief description of the drawings
[0022] FIGURE la is a perspective view of a capsule system 101 containing an array of nanofluidic biosensors 200. A solution 300 containing fluorescently-labeled biomolecules is deposited inside the capsule 101 by a pipet system 400. An optical system 500 based on a laser beam 510 is used for the measurement.
[0023] FIGURE lb is a perspective view of a surface 102 containing an array of nanofluidic biosensors 200. A solution 300 containing fluorescently-labeled biomolecules is deposited on the surface 102 by a pipet system 400. An optical system 500 based on a laser beam 510 is used for the measurement.
[0024] FIGURE 2a shows a cross section of the nanofluidic biosensor defined by two substrates 201 and 202 that are locally structured by areas 211 that are functionalized by biomarkers 310 and other areas 203 that prevent that functionalization. Reagent solution 300 containing biomolecules enter the nanochannel 210 and is actuated by the external driving component 241. The laser beam 510 monitors the photobleaching of the immobilized biomolecules 340 in the detection volume 520.
[0025] FIGURE 2b shows a cross section of the nanofluidic biosensor defined by two substrates 201 and 202. Only one of the substrates is locally structured by area 211 that is functionalized by biomarkers 310 and other areas 203 that prevent that functionalization. Reagent solution 300 containing biomolecules enter the nanochannel 210 and is actuated by the internal driving component 242. The laser beam 510 monitors the photobleaching of the immobilized biomolecules 340 in the detection volume 520.
[0026] FIGURE 3 illustrates the concentration evolution with time of specific biomolecules over the nanochannel length.
[0027] FIGURE 4 shows the concentration profile of specific biomolecules over the nanochannel length for a given time t\. The marked area represents the detected portion of specific biomolecules.
[0028] FIGURE 5 illustrates the concentration evolution with time of non-specific biomolecules (background) over the nanochannel length. [0029] FIGURE 6 shows the concentration profile of non-specific biomolecules over the nanochannel length for a given time t\. The marked area represents the detected portion of specific biomolecules, corresponding to the background noise.
[0030] FIGURE 7 illustrates a standard photobleaching curve of fluorophores attached to immobilized specific biomolecules.
[0031] FIGURE 8 illustrates the fluorescence intensity curve in function of time for non-specific biomolecules inside the nanochannel, showing that only background noise is detected.
[0032] FIGURE 9 shows the solution flow velocity inside the nanochannel in function of time.
Detailed description of the invention
[0033] As used herein, the term "biomolecules" is intended to be a generic term, which includes for example (but not limited to) proteins such as antibodies or cytokines, peptides, nucleic acids, lipid molecules, polysaccharides and virus.
[0034] As used herein, the term "nanochannel" is intended to be a generic term, which means well-defined microfabricated structure with at least one nanometer-sized dimension. The nanometer- sized dimension of the nanochannel is defined to be higher than 2 nm because of the size of the smallest biomolecules to be detected that have to enter into the slit and that are in the same order of magnitude. The present invention is limited to nanochannels with a height lower than one micron, because of the range of the detection volume of the optical system that are typically in the same order of magnitude.
[0035] The present invention aims to enhance the detection of biomolecules by increasing the probability of interactions with specific biomarkers due to the confinement of functionalized surfaces. As shown in FIGURE la and FIGURE lb, an array of nanofluidic biosensors 200 is immobilized in a capsule system 101 or on a surface 102. A mix solution 300 containing the fluorescently-labeled biomolecules of interest is disposed inside the capsule 101 or on the surface 102 by a pipet system 400. The capsule 101 may be hermetically closed in order to avoid contamination. Finally, an optical unit 500 is used to measure the biomolecular interactions inside the biosensors 200 by focusing the laser beam 510 inside the biosensors nanochannel.
[0036] FIGURE 2a and FIGURE 2b illustrate the principle of detection and the cross-section of a biosensor according to the invention. The system is composed of a nanochannel 210 linking a lateral input aperture 220 with a lateral output aperture 230. A driving component that can be external (241) or internal (242) is located next to the lateral output aperture 230. First, biomarkers 310 are immobilized on selectively functionalized nanochannel surfaces of one or both substrates 201 and 202. The other nanochannel surfaces and the lateral aperture surfaces may be protected by the deposition of a non-functionalized layer 203. The detection volume 520 has to be focused inside the nanochannel 210 such as the intersection volume defined by the volume of the nanochannel 210 and the detection volume 520 is maximal, and directly next to the lateral input aperture 220. Next, the solution 300 containing the fluorescently labeled specific biomolecules 320 and non-specific biomolecules 330 is filled into the system from the lateral input aperture 220 by capillarity. When reaching the driving component 241 or 242, the solution 300 fills the driving component by absorption for example, leading to a forced convective flow across the biosensor. When the driving component 241 or 242 achieves its maximum filling capacity, the convective flow stops and the system reaches equilibrium. During the convective flow and thanks to Brownian motion, biomolecules 320 interact with the biomarkers 310 immobilized inside the nanochannel 210 and may create molecular complexes 340. A concentration gradient is obtained across the nanochannel 210. The non-specific biomolecules 330 will diffuse in the nanochannel 210 but will not form molecular complexes with the immobilized biomarkers 310. Non-specific biomolecules 331 will be present in the lateral output aperture 230, and some 332 may also be present inside the driving component 241 or 242. When excited by the laser beam 510, the immobilized fluorescently emitting complexes 340 and the diffusing fluorescently emitting biomolecules 330 diffusing across the optical detection volume are both detected by the optical system.
[0037] The present invention is distinguishable from techniques currently being used to detect molecular interactions. The unique method of measuring the concentration of immobilized complexes across the selectively functionalized nanochannel being linked to lateral apertures is different from current techniques based on measuring interactions on a single surface or reservoir. These solutions do not benefit from the increased probability of interaction events that occur in the unique design presented in this patent.
[0038] FIGURE 3 shows the evolution of concentration with time across the biosensor when the solution contains specific biomolecules. Directly after the capillary filling, at time t0, there is a background concentration c0 of fluorescently labeled molecules inside the lateral input aperture. Specific biomolecules that enter into the nanochannel interact quickly with the nanochannel functionalized surfaces, leading to an increase of concentration (dashed curve). The maximum concentration csat corresponds to the case where, for a given x position, all biomarkers have interacted with specific biomolecules. In function of time, the concentration gradient will tend to the tlnf dotted curve, corresponding to the total saturation of the nanochannel biomarkers (dotted curve).
[0039] FIGURE 4 illustrates the concentration gradient across the biosensor at a time t1; corresponding to the case when the solution has already filled the biosensor as well as the absorbing component. Thanks to Brownian motion, the biomolecules continue to enter the nanochannel and continue to interact with the biomarkers, but depending on the background concentration c0, the transition to saturation tinf may be very long. This allows a stable measurement of the concentration profile across the nanochannel. The measurement volume (hatched area) corresponds to the intersection of the laser beam with a width b and the nanochannel.
[0040] FIGURE 5 shows the concentration evolution with time across the biosensor when the solution contains only non-specific biomolecules. Directly after the capillary filling, at time to, a background concentration Co of fluorescently labeled molecules is present inside the lateral input aperture and the nanochannel. No further concentration increase is expected as there is no interaction with the functionalized surfaces. In this case, the concentration Co remains constant for all x positions and with time.
[0041] FIGURE 6 illustrates the concentration gradient across the biosensor at a time ti, corresponding to the case when the solution contains no specific biomolecules and has already filled the biosensor as well as the absorbing component. The measurement volume (hatched area) corresponds to the intersection of the laser beam with a width b and the nanochannel. [0042] FIGURE 7 shows the fluorescence intensity evolution with time during measurement, for a given position inside the nanochannel, when the solution contains specific biomolecules. The measurement starts when the shutter of the optical system opens. A standard photobleaching curve is obtained containing quantitative information on the number of immobilized and fluorescently-labeled molecules present within the measurement volume.
[0043] FIGURE 8 shows the fluorescence intensity evolution with time during a measurement, for a given position inside the nanochannel, when the solution does not contain any specific biomolecules. The measurement starts when the shutter of the optical system opens. No photobleaching curve is obtained, since there are only diffusing fluorescently-labeled biomolecules inside the measurement volume leading to a constant background signal.
[0044] FIGURE 9 shows the evolution of the convective flow of the solution inside the nanochannel in function of time. First, the nanochannel is filled by capillarity during a time tcap, which results in an increase of the flow velocity. When reaching the absorbing component, the solution has completely filled the nanochannel and the flow is no more driven by capillarity but rather by absorption. This results in a change of flow velocity during a time tact. Finally, the solution flow inside the nanochannel tends to 0, and biomolecule movements are only due to Brownian motion. Measuring time tm should occur after the convective flow stopped.
[0045] According to the present invention, the device offers great improvements for the detection, enumeration, identification and characterization of biomolecules interacting or not with other immobilized biomolecules. Applications of the present invention can cover biomedical, biological or food analysis as well as fundamental studies in analytical and bioanalytical chemistry.

Claims

Claims
1. A biosensor (200) for detecting and quantifying fluorescently-labeled biomolecules (320); said biosensor (200) comprising a nanochannel (210) defined between two substrates (201, 202) and containing one or several selectively functionalized areas (211) on which are immobilized biomarkers (310), said nanochannel furthermore being defined by a lateral input aperture (220) and a lateral output aperture (230), said input aperture (220) being adapted to let a solution containing biomolecules (320) to enter said nanochannel (210) and said output aperture (230) adapted to drive said solution through said nanochannel (210) by capillarity.
2. Biosensor (200) according to claim 1 wherein said biomarkers (310) are adapted to biologically or chemically interact with specific biomolecules (320) and/or not interact with non-specific biomolecules (330) contained in said solution (300).
3. Biosensor (200) according to claim 1 or 2 wherein the substrates (201, 202) are made of a material selected from the group constituted of silicon, glass, plastic and oxide compounds.
4. Biosensor (200) according to any of the previous claims wherein the output aperture (230) is containing or is in contact with a driving component (241 or 242) adapted to drive said solution through said nanochannel (210).
5. Biosensor (200) according to any of the previous claims wherein non- functionalized surfaces inside the nanochannel (210) and the lateral apertures (220, 230) contain a thin layer of material selected from the group constituted of metallic, plastic and oxide compounds, having a thickness between 1 nm and 1000 nm.
6. Biosensor (200) according to any of the previous claims wherein the lateral apertures (220, 230) have an area from 100 nm 2 to 20 mm 2 and the nanochannel (210) a height between 2 nm and 1000 nm, a width between 2 nm and 20 mm, and a length between 2 nm and 20 mm.
7. An array comprising several biosensors (200) as defined in any of the previous claims, said biosensors (200) being fixed inside a capsule system (101) or on a surface (102).
8. Assembly consisting of one or several biosensors (200) as defined in any of the previous claims and comprising optical means (500) for fluorescence excitation and detection.
9. Assembly according to claim 8 wherein said optical means (500) is a fluorescence measurement unit comprising a detector which is a single-photon detector, such as a detector array (CMOS or CCD), an avalanche photodiode (APD) or a photomultiplier tube (PMT).
10. A method for detecting and quantifying the presence of fluorescently-labeled biomolecules (320) in a solution (300) that comprises:
a) at least one biosensor (200) as defined in any of claims 1 to 6;
b) a filling mechanism of said biosensor(s) (200) from lateral input apertures (220) to the lateral output aperture (230), crossing the nanochannel (210), by depositing an aqueous solution (300) containing fluorescently-labeled biomolecules (320 and or 330) that can be specific to biomarkers (310) immobilized in the nanochannel and not into the capsule system (101) or the surface (102).
c) an optical system (500);
d) the detection of specific biomolecules (320) immobilized on biomarkers (310) inside said nanochannel (210) by means of photobleaching of fluophores attached to the biomolecules (320) as well as the determination of the concentration gradient across the length of the nanochannel (210).
11. Method according to claim 10 wherein said biomolecules (320) are proteins, DNA, RNA, antibodies, amino acids, nucleic acids, enzymes, lipid molecules, peptides, polysaccharides or virus.
PCT/IB2012/050527 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof Ceased WO2012120387A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US14/003,277 US9547004B2 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
CN201280012408.XA CN103502795B (en) 2011-03-09 2012-02-06 The fast quantification of the biomolecule in the nano-fluid biology sensor of selectively functionalized and method thereof
EP12711449.4A EP2684027B1 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
AU2012226463A AU2012226463B2 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
JP2013557188A JP6130306B2 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules and methods in selectively functionalized nanofluidic biosensors
ES12711449T ES2767123T3 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
BR112013022952-7A BR112013022952B1 (en) 2011-03-09 2012-02-06 BIOSSENSOR, MATRIX UNDERSTANDING VARIOUS BIOSSENSORS, ASSEMBLY CONSISTING OF ONE OR VARIOUS BIOSSENSORS AND METHOD TO DETECT AND QUANTIFY THE PRESENCE OF BIOMOLECULES
HK14100834.4A HK1187982B (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
CA2829178A CA2829178C (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050979 2011-03-09
IBPCT/IB2011/050979 2011-03-09

Publications (1)

Publication Number Publication Date
WO2012120387A1 true WO2012120387A1 (en) 2012-09-13

Family

ID=45922721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050527 Ceased WO2012120387A1 (en) 2011-03-09 2012-02-06 Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof

Country Status (10)

Country Link
US (1) US9547004B2 (en)
EP (1) EP2684027B1 (en)
JP (1) JP6130306B2 (en)
CN (1) CN103502795B (en)
AU (1) AU2012226463B2 (en)
BR (1) BR112013022952B1 (en)
CA (1) CA2829178C (en)
ES (1) ES2767123T3 (en)
PT (1) PT2684027T (en)
WO (1) WO2012120387A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015007559A1 (en) * 2013-07-17 2015-01-22 Abionic Sa Method and device for bioassays
WO2015087178A1 (en) * 2013-12-13 2015-06-18 Abionic Sa Gas evacuation system for nanofluidic biosensor
CN106573240A (en) * 2014-07-03 2017-04-19 阿比奥尼克公司 Capsule for rapid molecular quantification of a fluid sample such as whole blood

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194838B2 (en) 2010-03-03 2015-11-24 Osaka University Method and device for identifying nucleotide, and method and device for determining nucleotide sequence of polynucleotide
EP3047282B1 (en) 2013-09-18 2019-05-15 Quantum Biosystems Inc. Biomolecule sequencing devices, systems and methods
JP2015077652A (en) 2013-10-16 2015-04-23 クオンタムバイオシステムズ株式会社 Nano-gap electrode and method for manufacturing same
KR20160130380A (en) * 2014-01-24 2016-11-11 퀀텀 바이오시스템즈 가부시키가이샤 Devices, systems and methods for sequencing biomolecules
CN104651500B (en) 2015-01-30 2017-06-30 华东理工大学 The preparation method and applications of aerolysin nanopore-channel
US10983135B2 (en) 2016-02-01 2021-04-20 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
CN115595360A (en) 2016-04-27 2023-01-13 因美纳剑桥有限公司（Gb） Systems and methods for measurement and sequencing of biomolecules
CN113324958A (en) * 2021-05-19 2021-08-31 江南大学 Rapid detection capillary tube for visually detecting heavy metal mercury and preparation method and application thereof
DE102022208445A1 (en) * 2022-08-15 2024-02-15 Carl Zeiss Microscopy Gmbh Improved FCS procedure

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH182409A (en) 1934-03-03 1936-02-15 Ig Farbenindustrie Ag Vaseline-like product.
WO2010042007A1 (en) * 2008-10-10 2010-04-15 Jonas Tegenfeldt Method for the mapping of the local at/gc ratio along dna
US20100267158A1 (en) * 2009-04-16 2010-10-21 Chou Stephen Y Electronic Detectors Inside Nanofluidic Channels For Detection, Analysis, and Manipulation of Molecules, Small Particles, and Small Samples of Material
US20100310421A1 (en) * 2009-05-28 2010-12-09 Nabsys, Inc. Devices and methods for analyzing biomolecules and probes bound thereto
WO2011064701A1 (en) * 2009-11-27 2011-06-03 Ecole Polytechnique Federale De Lausanne (Epfl) Nanofluidic biosensor and its use for rapid measurement of biomolecular interactions in solution and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978503A (en) * 1984-06-13 1990-12-18 Ares-Serono Research & Development Limited Partnership Devices for use in chemical test procedures
US4775637A (en) * 1984-12-10 1988-10-04 Purtec Limited An immunoassay apparatus having at least two waveguides and method for its use
US5637469A (en) * 1992-05-01 1997-06-10 Trustees Of The University Of Pennsylvania Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems
JP4010171B2 (en) * 2001-04-16 2007-11-21 東ソー株式会社 Microchannel structure, its manufacturing method and its use
CN1690711B (en) * 2004-04-23 2010-04-14 中国人民解放军军事医学科学院微生物流行病研究所 Immunochromatography test strip based on up-conversion luminescence technology
FR2890173B1 (en) * 2005-08-23 2008-02-22 Vedalab Sa DEVICE FOR DETERMINING AN ANALYTE IN A LIQUID SAMPLE BY A SANDWICH TEST AND A COMPETITION TEST
US8586316B2 (en) * 2008-02-07 2013-11-19 The Board Of Regents Of The University Of Texas System Methods for detecting molecule-molecule interactions with a single detection channel
KR101226957B1 (en) * 2008-12-08 2013-02-07 한국전자통신연구원 Disposable diagnostic kit
US20130034863A1 (en) 2009-01-23 2013-02-07 Philadelphia Health And Education Corporation Apparatus and Methods for Detecting Inflammation Using Quantum Dots

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH182409A (en) 1934-03-03 1936-02-15 Ig Farbenindustrie Ag Vaseline-like product.
WO2010042007A1 (en) * 2008-10-10 2010-04-15 Jonas Tegenfeldt Method for the mapping of the local at/gc ratio along dna
US20100267158A1 (en) * 2009-04-16 2010-10-21 Chou Stephen Y Electronic Detectors Inside Nanofluidic Channels For Detection, Analysis, and Manipulation of Molecules, Small Particles, and Small Samples of Material
US20100310421A1 (en) * 2009-05-28 2010-12-09 Nabsys, Inc. Devices and methods for analyzing biomolecules and probes bound thereto
WO2011064701A1 (en) * 2009-11-27 2011-06-03 Ecole Polytechnique Federale De Lausanne (Epfl) Nanofluidic biosensor and its use for rapid measurement of biomolecular interactions in solution and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYUBONG JO ET AL: "A single-molecule barcoding system using nanoslits for DNA analysis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 8, 20 February 2007 (2007-02-20), pages 2673 - 2678, XP002630573, ISSN: 0027-8424, [retrieved on 20070212], DOI: 10.1073/PNAS.0611151104 *
PO-KENG LIN ET AL: "One-dimensional dynamics and transport of dna molecules in a quasi-two-dimensional nanoslit", MACROMOLECULES, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC; US, vol. 42, no. 5, 10 March 2009 (2009-03-10), pages 1770 - 1774, XP002630572, ISSN: 0024-9297, [retrieved on 20090210], DOI: 10.1021/MA8021037 *
SEUNG YUN YANG ET AL: "DNA-Functionalized Nanochannels for SNP Detection", NANO LETTERS, vol. 11, no. 3, 16 February 2011 (2011-02-16), pages 1032 - 1035, XP055027554, ISSN: 1530-6984, DOI: 10.1021/nl200357y *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015007559A1 (en) * 2013-07-17 2015-01-22 Abionic Sa Method and device for bioassays
US9989526B2 (en) 2013-07-17 2018-06-05 Abionic Sa Method and device for bioassays
WO2015087178A1 (en) * 2013-12-13 2015-06-18 Abionic Sa Gas evacuation system for nanofluidic biosensor
CN105874320A (en) * 2013-12-13 2016-08-17 阿比奥尼克公司 Gas Evacuation System for Nanofluidic Biosensors
JP2017505446A (en) * 2013-12-13 2017-02-16 アビオニック・ソシエテ・アノニム Gas discharge system for nanofluidic biosensor
US10166540B2 (en) 2013-12-13 2019-01-01 Abionic Sa Gas evacuation system for nanofluidic biosensor
AU2014363071B2 (en) * 2013-12-13 2019-05-02 Abionic Sa Gas evacuation system for nanofluidic biosensor
CN105874320B (en) * 2013-12-13 2019-08-30 阿比奥尼克公司 Gas Evacuation System for Nanofluidic Biosensors
CN106573240A (en) * 2014-07-03 2017-04-19 阿比奥尼克公司 Capsule for rapid molecular quantification of a fluid sample such as whole blood
US20170197210A1 (en) * 2014-07-03 2017-07-13 Abionic Sa Capsule for Rapid Molecular Quantification of a Fluid Sample Such as Whole Blood
US10434508B2 (en) 2014-07-03 2019-10-08 Abionic Sa Capsule for rapid molecular quantification of a fluid sample such as whole blood
AU2015283689B2 (en) * 2014-07-03 2020-07-16 Abionic Sa Capsule for rapid molecular quantification of a fluid sample such as whole blood

Also Published As

Publication number Publication date
CA2829178A1 (en) 2012-09-13
BR112013022952B1 (en) 2020-09-08
HK1187982A1 (en) 2014-04-17
US9547004B2 (en) 2017-01-17
JP6130306B2 (en) 2017-05-17
AU2012226463B2 (en) 2015-03-12
EP2684027A1 (en) 2014-01-15
JP2014507668A (en) 2014-03-27
CN103502795B (en) 2016-02-24
PT2684027T (en) 2020-01-27
CA2829178C (en) 2020-01-07
ES2767123T3 (en) 2020-06-16
US20140256573A1 (en) 2014-09-11
CN103502795A (en) 2014-01-08
EP2684027B1 (en) 2019-12-11
AU2012226463A1 (en) 2013-10-10
BR112013022952A2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
CA2829178C (en) Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
AU2010322751B2 (en) Nanofluidic biosensor and its use for rapid measurement of biomolecular interactions in solution and methods
EP3021968B1 (en) Method and device for bioassays
CA2932577C (en) Gas evacuation system for nanofluidic biosensor
HK1187982B (en) Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
HK1219456B (en) Method and device for bioassays
HK1175527B (en) Nanofluidic biosensor and its use for rapid measurement of biomolecular interactions in solution and methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280012408.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12711449

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012711449

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2829178

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013557188

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012226463

Country of ref document: AU

Date of ref document: 20120206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14003277

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013022952

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013022952

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130906